SynthesisHaematologica2010
Combined modality treatment improves tumor control and overall survival in patients with early stage Hodgkin's lymphoma: a systematic review.
Synthesis in Haematologica, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it, 109 citations in OpenAlex.
- Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second malignant neoplasms, overall and progression-free survival: individual participant data analysis.The Cochrane database of systematic reviews · 2017Pooled it
- Efficacy of abbreviated Stanford V chemotherapy and involved-field radiotherapy in early-stage Hodgkin lymphoma: mature results of the G4 trial.Annals of oncology : official journal of the European Society for Medical Oncology · 2013Trial
- Predicting Absolute Risk of First Relapse in Classical Hodgkin Lymphoma by Incorporating Contemporary Treatment Effects.Cancers · 2025Article
- Treatment outcomes of ABVD in classical Hodgkin lymphoma patients from Thailand without procarbazine access.Scientific reports · 2025Article
- Unlocking the Therapeutic Potential of Algae-Derived Compounds in Hematological Malignancies.Cancers · 2025Review
- Clinical evaluation of deep learning-enhanced lymphoma pet imaging with accelerated acquisition.Journal of applied clinical medical physics · 2024Article
- Advances in antibody-based therapy in oncology.Nature cancer · 2023Review
- Proton linear energy transfer and variable relative biological effectiveness for adolescent patients with Hodgkin lymphoma.BJR open · 2023Article
- Impact of radiation techniques on lung toxicity in patients with mediastinal Hodgkin's lymphoma.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2021Article
- Biological optimization for mediastinal lymphoma radiotherapy - a preliminary study.Acta oncologica (Stockholm, Sweden) · 2020Article
- Resources-Stratified Guidelines for Classical Hodgkin Lymphoma.International journal of environmental research and public health · 2020Review
- Association of Combined Modality Therapy vs Chemotherapy Alone With Overall Survival in Early-Stage Pediatric Hodgkin Lymphoma.JAMA oncology · 2019Observational
- Overview and outcome of Hodgkin's Lymphoma: Experience of a single developing country's oncology centre.PloS one · 2018Article
- Role of Radiation Therapy in the Treatment of Hodgkin Lymphoma.Current hematologic malignancy reports · 2017Review
- ACR Appropriateness Criteria® Hodgkin Lymphoma-Favorable Prognosis Stage I and II.American journal of clinical oncology · 2016Review
- Exploring Big Data in Hematological Malignancies: Challenges and Opportunities.Current hematologic malignancy reports · 2016Review
- Predictors of radiation pneumonitis in patients receiving intensity modulated radiation therapy for Hodgkin and non-Hodgkin lymphoma.International journal of radiation oncology, biology, physics · 2015Article
- Chemotherapy only in early-stage Hodgkin lymphoma: more relapses but "same" (or possibly worse) survival--reconsidering the misguided trend to omit radiotherapy.Current hematologic malignancy reports · 2014Review
- The Evolving Role of Radiotherapy in Early Stage Hodgkin's Lymphoma.Mediterranean journal of hematology and infectious diseases · 2014Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Combined modality treatment (CMT) of chemotherapy followed by localized radiotherapy is standard treatment for patients with early stage Hodgkin's lymphoma. However, the role of radiotherapy has been questioned recently and some clinical study groups advocate chemotherapy only for this indication. We thus performed a systematic review with meta-analysis of randomized controlled trials comparing chemotherapy alone with CMT in patients with early stage Hodgkin's lymphoma with respect to response rate, tumor control and overall survival (OS). We searched Medline, EMBASE and the Cochrane Library as well as conference proceedings from January 1980 to February 2009 for randomized controlled trials comparing chemotherapy alone versus the same chemotherapy regimen plus radiotherapy. Progression free survival and similar outcomes were analyzed together as tumor control. Effect measures used were hazard ratios for OS and tumor control as well as relative risks for complete response (CR). Meta-analyses were performed using RevMan5. Five randomized controlled trials involving 1,245 patients were included. The hazard ratio (HR) was 0.41 (95% confidence interval (CI) 0.25 to 0.66) for tumor control and 0.40 (95% CI 0.27 to 0.59) for OS for patients receiving CMT compared to chemotherapy alone. CR rates were similar between treatment groups. In sensitivity analyses another 6 trials were included that did not fulfill the inclusion criteria of our protocol but were considered relevant to the topic. These trials underlined the results of the main analysis. In conclusion, adding radiotherapy to chemotherapy improves tumor control and OS in patients with early stage Hodgkin's lymphoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.